☆ 4.4 Article

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

Amanda M. Johnson et al.

Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries

He Zhou et al.

Summary: This systematic review and meta-analysis evaluated the safety and effectiveness of Ustekinumab (UST) in patients with inflammatory bowel disease (IBD) in Eastern and Western countries. The results showed that UST is an effective drug for IBD and its effectiveness on CD patients in Eastern countries is comparable to that in Western countries.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness and safety of ustekinumab in bio-naive Crohn's disease patients: a multicentre observational retrospective study

Valdes Delgado Teresa et al.

Summary: This study evaluated the effectiveness and safety of ustekinumab in bio-naive patients with Crohn's disease. The results showed that ustekinumab had high rates of clinical and biological remission and a favorable safety profile. It suggests that ustekinumab could be considered as a first-line therapy for Crohn's disease patients.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases

Hongsheng Yang et al.

Summary: Ustekinumab is effective in treating CD and UC, with a risk of LOR and dose escalation of 21% and 25% respectively in CD patients. After dose escalation, 58% of patients regain clinical response. Limited data is available for LOR in UC patients, but dose escalation has shown a risk of 18% and a remission rate of 58%.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Review Gastroenterology & Hepatology

Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis

Joseph Meserve et al.

Summary: Ustekinumab dose escalation was effective in achieving response in patients with active CD who had inadequate response or loss of response to standard dose induction and/or maintenance therapy.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

P433 Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc

M Garcia-Alvarado et al.

Journal of Crohns & Colitis (2022)

Add to Collection

Review Gastroenterology & Hepatology

Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Sailish Honap et al.

Summary: In this comprehensive systematic review and meta-analysis, ustekinumab has been shown to be effective and safe in the real-world treatment of inflammatory bowel disease (IBD), with sustained efficacy for both Crohn's disease (CD) and ulcerative colitis (UC).

DIGESTIVE DISEASES AND SCIENCES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis

Dahham Alsoud et al.

Summary: UST treatment can achieve histological remission in refractory UC patients. There is a strong correlation between serum UST concentrations and tissue drug exposure, indicating limited value in measuring tissue exposure.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response

Valerie Heron et al.

Journal of the Canadian Association of Gastroenterology (2022)

Add to Collection

Article Gastroenterology & Hepatology

Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

Tessa Straatmijer et al.

Summary: In Crohn's disease patients treated with ustekinumab, one-third achieved corticosteroid-free clinical remission after 104 weeks, with 64.3% and 54.8% remaining on treatment at 52 and 104 weeks, respectively.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy

Uri Kopylov et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Health Care Sciences & Services

Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease

Rahel Ehrenberg et al.

JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2020)

Add to Collection

Article Medicine, General & Internal

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

B. E. Sands et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease

Yun Qiu et al.

JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease

B. G. Feagan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

C. Ma et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

Add to Collection

Review Gastroenterology & Hepatology

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

Vincent Billioud et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.